<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="https://www.taxtmi.com/rss_sitemap/rss_feed_blog.xsl?v=1750492856"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights</title>
    <link>https://www.taxtmi.com/news?id=58999</link>
    <description>Illumina&#039;s 5-base solution enables simultaneous genomic variant detection and single-base DNA methylation profiling from one sample by combining selective conversion chemistry with DRAGEN algorithms. Two kits-whole genome and targeted enrichment-are compatible with NovaSeq and NextSeq 2000 systems, and Illumina Connected Multiomics provides integrated visualization and interpretation to support biomarker discovery and multiomic research. The release notes commercial availability after early access, applications in rare disease and oncology, and standard forward looking risk disclosures concerning development, manufacturing, suppliers, and customer acceptance.</description>
    <language>en-us</language>
    <pubDate>Thu, 16 Oct 2025 11:46:03 +0530</pubDate>
    <lastBuildDate>Thu, 16 Oct 2025 11:46:03 +0530</lastBuildDate>
    <generator>TaxTMI RSS Generator</generator>
    <atom:link href="https://www.taxtmi.com/rss_feed_blog?id=858901" rel="self" type="application/rss+xml"/>
    <item>
      <title>Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights</title>
      <link>https://www.taxtmi.com/news?id=58999</link>
      <description>Illumina&#039;s 5-base solution enables simultaneous genomic variant detection and single-base DNA methylation profiling from one sample by combining selective conversion chemistry with DRAGEN algorithms. Two kits-whole genome and targeted enrichment-are compatible with NovaSeq and NextSeq 2000 systems, and Illumina Connected Multiomics provides integrated visualization and interpretation to support biomarker discovery and multiomic research. The release notes commercial availability after early access, applications in rare disease and oncology, and standard forward looking risk disclosures concerning development, manufacturing, suppliers, and customer acceptance.</description>
      <category>News</category>
      <law>-</law>
      <pubDate>Thu, 16 Oct 2025 11:46:03 +0530</pubDate>
      <guid isPermaLink="true">https://www.taxtmi.com/news?id=58999</guid>
    </item>
  </channel>
</rss>